The role of IL-1β in the bone loss during rheumatic diseases

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Ruscitti, Piero ^a   Cipriani, Paola ^a   Carubbi, Francesco ^a   Liakouli, Vasiliki ^a   Zazzeroni, Francesca ^a   Di Benedetto, Paola ^a   Berardicurti, Onorina ^a   Alesse, Edoardo ^a   Giacomelli, Roberto ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1BETA; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; CYTOKINE; LIGAND;

AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; BONE DISEASE; BONE METABOLISM; CLINICAL TRIAL (TOPIC); HUMAN; OSTEOCLAST ACTIVITY; OSTEOLYSIS; OSTEOMYELITIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; UPREGULATION; ANIMAL; BONE; CYTOLOGY; INFLAMMATION; METABOLISM; OSTEOCLAST; PATHOLOGY; SPONDYLARTHRITIS;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BONE AND BONES; BONE RESORPTION; CYTOKINES; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; LIGANDS; OSTEOCLASTS; OSTEOMYELITIS; RHEUMATIC DISEASES; SPONDYLARTHRITIS;

EID: 84928822514     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/782382     Document Type: Review

References (112)

1. G. R. Mundy, "Osteoporosis and inflammation," Nutrition Reviews, vol. 65, no. 12, pp. S147-S151, 2007.
2. E. Romas, M. T. Gillespie, and T. J. Martin, "Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis," Bone, vol. 30, no. 2, pp. 340-346, 2002.
3. E. F. Eriksen, "Cellular mechanisms of bone remodeling," Reviews in Endocrine and Metabolic Disorders, vol. 11, no. 4, pp. 219-227, 2010.
4. L. G. Raisz and G. A. Rodan, "Pathogenesis of osteoporosis," Endocrinology and Metabolism Clinics of North America, vol. 32, no. 1, pp. 15-24, 2003.
5. Y.-Y. Kung, U. Felge, I. Sarosi et al., "Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand," Nature, vol. 402, no. 6759, pp. 304-309, 1999.
6. C. Roggia, Y. Gao, S. Cenci et al., "Up-regulation of TNFproducing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 24, pp. 13960-13965, 2001.
7. K. Redlich and J. S. Smolen, "Inflammatory bone loss: pathogenesis and therapeutic intervention," Nature Reviews Drug Discovery, vol. 11, no. 3, pp. 234-250, 2012.
8. E. Romas and M. T. Gillespie, "Inflammation-induced bone loss: can it be prevented?" Rheumatic Disease Clinics of North America, vol. 32, no. 4, pp. 759-773, 2006.
9. J. E. Horton, L. G. Raisz, H. A. Simmons, J. J. Oppenheim, and S. E. Mergenhagen, "Bone resorbing activity in supernatant fluid fromcultured human peripheral blood leukocytes," Science, vol. 177, no. 4051, pp. 793-795, 1972.
10. J. Lorenzo, M. Horowitz, and Y. Choi, "Osteoimmunology: interactions of the bone and immune system," Endocrine Reviews, vol. 29, no. 4, pp. 403-440, 2008.
11. C. Garlanda, C. A. Dinarello, and A. Mantovani, "The interleukin-1 family: back to the future," Immunity, vol. 39, no. 6, pp. 1003-1018, 2013.
12. C. A. Dinarello, "Overview of the interleukin-1 family of ligands and receptors," Seminars in Immunology, vol. 25, no. 6, pp. 389-393, 2013.
13. J. A. Lorenzo, S. L. Sousa, C. Alander, L. G. Raisz, and C. A. Dinarello, "Comparison of the bone-resorbing activity in the supernatants from phytohemagglutinin-stimulated human peripheral blood mononuclear cells with that of cytokines through the use of an antiserumto interleukin 1," Endocrinology, vol. 121, no. 3, pp. 1164-1170, 1987.
14. I. Nakamura and E. Jimi, "Regulation of osteoclast differentiation and function by interleukin-1," Vitamins & Hormones, vol. 74, pp. 357-370, 2006.
15. X. Lu, L. Gilbert, X. He, J. Rubin, and M. S. Nanes, "Transcriptional regulation of the osterix (Osx, Sp7) promoter by tumor necrosis factor identifies disparate effects of mitogen-activated protein kinase and NFκB pathways," The Journal of Biological Chemistry, vol. 281, no. 10, pp. 6297-6306, 2006.
16. D. Diarra, M. Stolina, K. Polzer et al., "Dickkopf-1 is a master regulator of joint remodeling," Nature Medicine, vol. 13, no. 2, pp. 156-163, 2007.
17. A. Corrado, A. Neve, N. Maruotti, and F. P. Cantatore, "Bone effects of biologic drugs in rheumatoid arthritis," Clinical and Developmental Immunology, vol. 2013, Article ID 945945, 7 pages, 2013.
18. S.-K. Lee, A. E. Gardner, J. F. Kalinowski, S. L. Jastrzebski, and J. A. Lorenzo, "RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production," Bone, vol. 38, no. 5, pp. 678-685, 2006.
19. S.-K. Lee, J. Kalinowski, S. Jastrzebski, and J. A. Lorenzo, "1,25 (OH)2 vitamin D3-stimulated osteoclast formation in spleenosteoblast cocultures is mediated in part by enhanced IL-1α and receptor activator of NF-κB ligand production in osteoblasts," Journal of Immunology, vol. 169, no. 5, pp. 2374-2380, 2002.
20. K. Polzer, L. Joosten, J. Gasser et al., "Interleukin-1 is essential for systemic inflammatory bone loss," Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 284-290, 2010.
21. P. G. S. Lacativa and M. L. F. de Farias, "Osteoporosis and inflammation," Arquivos Brasileiros de Endocrinologia & Metabologia, vol. 54, no. 2, pp. 123-132, 2010.
22. M. N. Weitzmann and R. Pacifici, "The role of T lymphocytes in bone metabolism," Immunological Reviews, vol. 208, pp. 154-168, 2005.
23. H.-Y. Chen, W.-C. Chen, M.-C. Wu, F.-J. Tsai, and C.-C. Lin, "Interleukin-1β and interleukin-1 receptor antagonist gene polymorphism in postmenopausal women: correlation to bone mineral density and susceptibility to osteoporosis," Maturitas, vol. 44, no. 1, pp. 49-54, 2003.
24. T.-H. Chao, H.-N. Yu, C.-C. Huang, W.-S. Liu, Y.-W. Tsai, and W.-T. Wu, "Association of interleukin-1 beta (-511C/T) polymorphisms with osteoporosis in postmenopausal women," Annals of Saudi Medicine, vol. 30, no. 6, pp. 437-441, 2010.
25. B. L. Langdahl, E. Løkke, M. Carstens, L. L. Stenkjær, and E. F. Eriksen, "Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1-receptor antagonist gene but not with polymorphisms in the interleukin- 1β gene," Journal of Bone and Mineral Research, vol. 15, no. 3, pp. 402-414, 2000.
26. S. Knudsen, T. Harsløf, L. B. Husted, M. Carstens, L. Stenkjær, and B. L. Langdahl, "The effect of interleukin-1α polymorphisms on bone mineral density and the risk of vertebral fractures," Calcified Tissue International, vol. 80, no. 1, pp. 21-30, 2007.
27. M. Gass and B. Dawson-Hughes, "Preventing osteoporosisrelated fractures: an overview," The American Journal of Medicine, vol. 119, no. 4, pp. S3-S11, 2006.
28. R. B. Kimble, A. B. Matayoshi, J. L. Vannice, V. T. Kung, C. Williams, and R. Pacifici, "Simultaneous block of interleukin- 1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period," Endocrinology, vol. 136, no. 7, pp. 3054-3061, 1995.
29. J. A. Lorenzo, A. Naprta, Y. Rao et al., "Mice lacking the type I interleukin-1 receptor do not lose bonemass after ovariectomy," Endocrinology, vol. 139, no. 6, pp. 3022-3025, 1998.
30. R. Pacifici, C. Brown, E. Puscheck et al., "Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 12, pp. 5134-5138, 1991.
31. N. Charatcharoenwitthaya, S. Khosla, E. J. Atkinson, L. K. McCready, and B. L. Riggs, "Effect of blockade of TNF-α and interleukin-1 action on bone resorption in early postmenopausal women," Journal of Bone and Mineral Research, vol. 22, no. 5, pp. 724-729, 2007.
32. S. Guiducci, A. Del Rosso, M. Cinelli et al., "Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis," Arthritis Research & Therapy, vol. 7, no. 6, pp. R1244-R1253, 2005.
33. U. Dundar, V. Kavuncu, I. H. Ciftci, D. Evcik, O. Solak, and T. Cakir, "The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study," Journal of Bone and Mineral Metabolism, vol. 27, no. 4, pp. 464-470, 2009.
34. V. Strand and A. F. Kavanaugh, "The role of interleukin- 1 in bone resorption in rheumatoid arthritis," Rheumatology (Oxford), vol. 43, supplement 3, pp. iii10-iii16, 2004.
35. W. P. Arend, "Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist," Seminars in Arthritis and Rheumatism, vol. 30, supplement 2, no. 5, pp. 1-6, 2001.
36. K. Okano, T. Tsukazaki, A. Ohtsuru et al., "Parathyroid hormone-related peptide in synovial fluid and disease activity of rheumatoid arthritis," British Journal of Rheumatology, vol. 35, no. 11, pp. 1056-1062, 1996.
37. J. L. Funk, L. A. Cordaro, H. Wei, J. B. Benjamin, and D. E. Yocum, "Synovium as a source of increased amino-terminal parathyroid hormone-related protein expression in rheumatoid arthritis. A possible role for locally produced parathyroid hormone-related protein in the pathogenesis of rheumatoid arthritis," The Journal of Clinical Investigation, vol. 101, no. 7, pp. 1362-1371, 1998.
38. W. Sriarj, K. Aoki, K. Ohya, M. Takahashi, Y. Takagi, and H. Shimokawa, "TGF-β in dentinmatrix extract induces osteoclastogenesis in vitro," Odontology, vol. 103, no. 1, pp. 9-18, 2015.
39. J. E. Compston, E. O. Crawley, C. Evans, and M.M. O'Sullivan, "Spinal trabecular bone mineral content in patients with nonsteroid treated rheumatoid arthritis," Annals of the Rheumatic Diseases, vol. 47, no. 8, pp. 660-664, 1988.
40. R. Caporali, S. Gentile, M. Caprotti, and C. Montecucco, "Serum osteocalin (bone Gla-protein) and steroid osteoporosis in rheumatoid arthritis," The Journal of Rheumatology, vol. 18, no. 1, pp. 148-149, 1991.
41. S. C. Ghivizzani, R. Kang, H. I. Georgescu et al., "Constitutive intra-articular expression of human IL-1β following gene transfer to rabbit synoviumproduces allmajor pathologies of human rheumatoid arthritis," The Journal of Immunology, vol. 159, no. 7, pp. 3604-3612, 1997.
42. R. Horai, S. Saijo, H. Tanioka et al., "Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin I receptor antagonist-deficient mice," The Journal of Experimental Medicine, vol. 191, no. 2, pp. 313-320, 2000.
43. L. L. Johnson, R. Dyer, and D. J. Hupe, "Matrix metalloproteinases," Current Opinion in Chemical Biology, vol. 2, no. 4, pp. 466-471, 1998.
44. E. M. Gravallese, C. Manning, A. Tsay et al., "Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor," Arthritis & Rheumatism, vol. 43, no. 2, pp. 250-258, 2000.
45. H. Takayanagi, H. Iizuka, T. Juji et al., "Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis," Arthritis & Rheumatism, vol. 43, no. 2, pp. 259-269, 2000.
46. Y.-Y. Kong, U. Feige, I. Sarosi et al., "Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand," Nature, vol. 402, no. 6759, pp. 304-309, 1999.
47. W. B. van den Berg and B. Bresnihan, "Pathogenesis of joint damage in rheumatoid arthritis: evidence of a dominant role for interleukin-I," Baillieres Best Practice Research in Clinical Rheumatology, vol. 13, pp. 577-597, 1999.
48. L. A. B. Joosten, M. M. A. Helsen, F. A. J. Van De Loo, and W. B. Van Den Berg, "Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta, and IL-1Ra," Arthritis and Rheumatism, vol. 58, supplement 2, pp. S110-S122, 2008.
49. L. A. B. Joosten, M. M. A. Helsen, T. Saxne, F.A. J. van de Loo, D. Heinegård, and W. B. van den Berg, "IL-1αβ blockade prevents cartilage and bone destruction in murine type II collageninduced arthritis, whereas TNF-α blockade only ameliorates joint inflammation," The Journal of Immunology, vol. 163, no. 9, pp. 5049-5055, 1999.
50. S. S. Makarov, J. C. Olsen, W. N. Johnston et al., "Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA," Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 1, pp. 402-406, 1996.
51. K. Otani, I. Nita, W. Macaulay, H. I. Georgescu, P. D. Robbins, and C. H. Evans, "Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy," The Journal of Immunology, vol. 156, no. 9, pp. 3558-3562, 1996.
52. U. Müller-Ladner, C. R. Roberts, B. N. Franklin et al., "Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective," The Journal of Immunology, vol. 158, no. 7, pp. 3492-3498, 1997.
53. B. Bresnihan, J. M. Alvaro-Gracia, M. Cobby et al., "Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist," Arthritis & Rheumatism, vol. 41, no. 12, pp. 2196-2204.
54. Y. Jiang, H. K. Genant, I. Watt et al., "A multicenter, doubleblind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of genant and larsen scores," Arthritis & Rheumatism, vol. 43, no. 5, pp. 1001-1009, 2000.
55. M. Mertens and J. A. Singh, "Anakinra for rheumatoid arthritis," Cochrane Database Systematic Review, no. 1, Article ID CD005121, 2009.
56. M. Corr, "Spondyloarthropathy: frontier formolecular targets?" Expert Review of Clinical Immunology, vol. 9, no. 4, pp. 289-291, 2013.
57. C. Roux, "Osteoporosis in inflammatory joint diseases," Osteoporosis International, vol. 22, no. 2, pp. 421-433, 2011.
58. D. Mitra, D. M. Elvins, D. J. Speden, and A. J. Collins, "The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density," Rheumatology, vol. 39, no. 1, pp. 85-89, 2000.
59. E. Feldtkeller, D. Vosse, P. Geusens, and S. van der Linden, "Prevalence and annual incidence of vertebral fractures in patients with ankylosing spondylitis," Rheumatology International, vol. 26, no. 3, pp. 234-239, 2006.
60. P. Geusens, D. Vosse, and S. van der Linden, "Osteoporosis and vertebral fractures in ankylosing spondylitis," Current Opinion in Rheumatology, vol. 19, no. 4, pp. 335-339, 2007.
61. I. Ghozlani, M. Ghazi, A. Nouijai et al., "Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis," Bone, vol. 44, no. 5, pp. 772-776, 2009.
62. J. Gratacos, A. Collado, X. Filella et al., "Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity," British Journal of Rheumatology, vol. 33, no. 10, pp. 927-931, 1994.
63. H. Franck, T. Meurer, and L. C. Hofbauer, "Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis," The Journal of Rheumatology, vol. 31, no. 11, pp. 2236-2241, 2004.
64. H. Appel, M. Kuhne, S. Spiekermann et al., "Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis," Arthritis & Rheumatism, vol. 54, no. 9, pp. 2845-2851, 2006.
65. P. Machado, "Anti-tumor necrosis factor and new bone formation in ankylosing spondylitis: the controversy continues," Arthritis & Rheumatism, vol. 65, no. 10, pp. 2537-2540, 2013.
66. B. Osta, G. Benedetti, and P. Miossec, "Classical and paradoxical effects of TNF-α on bone homeostasis," Frontiers in Immunology, vol. 5, article 48, 2014.
67. H. S. Hreggvidsdottir, T. Noordenbos, and D. L. Baeten, "Inflammatory pathways in spondyloarthritis," Molecular Immunology, vol. 57, no. 1, pp. 28-37, 2014.
68. J. Braun and J. Sieper, "Ankylosing spondylitis," The Lancet, vol. 369, no. 9570, pp. 1379-1390, 2007.
69. D. van der Heijde, D. Salonen, B. N. Weissman et al., "Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years," Arthritis Research & Therapy, vol. 11, article R127, 2009.
70. D. I. Daikh and P. P. Chen, "Advances in managing ankylosing spondylitis," F1000Prime Reports, vol. 6, p. 78, 2014.
71. H. Haibel, M. Rudwaleit, J. Listing, and J. Sieper, "Open label trial of anakinra in active ankylosing spondylitis over 24 weeks," Annals of the Rheumatic Diseases, vol. 64, no. 2, pp. 296-298, 2005.
72. N. Maruotti, A. Corrado, and F.P. Cantatore, "Osteoporosis and rheumatic diseases," Reumatismo, vol. 66, no. 2, pp. 125-135, 2014.
73. H. Takayanagi, "Osteoimmunology and the effects of the immune system on bone," Nature Reviews Rheumatology, vol. 5, no. 12, pp. 667-676, 2009.
74. E. Svenungsson, G.-Z. Fei, K. Jensen-Urstad, U. de Faire, A. Hamsten, and J. Frostegård, "TNF-α: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease," Lupus, vol. 12, no. 6, pp. 454-461, 2003.
75. L. Gilbert, X. He, P. Farmer et al., "Inhibition of osteoblast differentiation by tumor necrosis factor-alpha," Endocrinology, vol. 141, no. 11, pp. 3956-3964, 2000.
76. E. J. Moerman, K. Teng, D. A. Lipschitz, and B. Lecka-Czernik, "Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways," Aging Cell, vol. 3, no. 6, pp. 379-389, 2004.
77. S. Y. Yuen, B. Rochwerg, J. Ouimet, and J. E. Pope, "Patients with scleroderma may have increased risk of osteoporosis. A comparison to rheumatoid arthritis and noninflammatory musculoskeletal conditions," Journal of Rheumatology, vol. 35, no. 6, pp. 1073-1078, 2008.
78. G. La Montagna, M. Vatti, G. Valentini, and G. Tirri, "Osteopenia in systemic sclerosis. Evidence of a participating role of earliermenopause," Clinical Rheumatology, vol. 10, no. 1, pp. 18-22, 1991.
79. D. C. O. de Andrade, S. C. D. M. Souza, J. F. de Carvalho et al., "High frequency of osteoporosis and fractures in women with dermatomyositis/polymyositis," Rheumatology International, vol. 32, no. 6, pp. 1549-1553, 2012.
80. A. Bicer, U. Tursen, T. I. Kaya et al., "Bone mineral density in patients with Behçet's disease," Rheumatology International, vol. 24, no. 6, pp. 355-358, 2004.
81. S. M. Stern and P. J. Ferguson, "Autoinflammatory bone diseases," Rheumatic Disease Clinics of North America, vol. 39, no. 4, pp. 735-749, 2013.
82. A. Jansson, E. D. Renner, J. Ramser et al., "Classification of nonbacterial osteitis: retrospective study of clinical, immunological and genetic aspects in 89 patients," Rheumatology, vol. 46, no. 1, pp. 154-160, 2007.
83. H. J. Girschick, C. Zimmer, G. Klaus, K. Darge, A. Dick, and H. Morbach, "Chronic recurrent multifocal osteomyelitis: what is it and how should it be treated?" Nature Clinical Practice Rheumatology, vol. 3, no. 12, pp. 733-738, 2007.
84. S. L. Masters, A. Simon, I. Aksentijevich, and D. L. Kastner, "Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease," Annual Review of Immunology, vol. 27, pp. 621-668, 2009.
85. S. R. Hofmann, T. Schwarz, J. C. Möller et al., "Chronic nonbacterial osteomyelitis is associated with impaired Sp1 signaling, reduced IL10 promoter phosphorylation, and reduced myeloid IL-10 expression," Clinical Immunology, vol. 141, no. 3, pp. 317-327, 2011.
86. C. Beck, H. Morbach, M. Beer et al., "Chronic nonbacterial osteomyelitis in childhood: prospective follow-up during the first year of anti-inflammatory treatment," Arthritis Research & Therapy, vol. 12, no. 2, article 74, 2010.
87. J. C. Abril and A. Ramirez, "Successful treatment of chronic recurrentmultifocal osteomyelitis with indomethacin: a preliminary report of five cases," Journal of Pediatric Orthopaedics, vol. 27, no. 5, pp. 587-591, 2007.
88. M. Twilt and R. M. Laxer, "Clinical care of children with sterile bone inflammation," Current Opinion in Rheumatology, vol. 23, no. 5, pp. 424-431, 2011.
89. A. Deutschmann, C. J. Mache, K. Bodo, D. Zebedin, and E. Ring, "Successful treatment of chronic recurrent multifocal osteomyelitiswith tumor necrosis factor-α blockage," Pediatrics, vol. 116, no. 5, pp. 1231-1233, 2005.
90. A. Borzutzky, S. Stern, A. Reiff et al., "Pediatric chronic nonbacterial osteomyelitis," Pediatrics, vol. 130, no. 5, pp. e1190-e1197, 2012.
91. H. Gleeson, E. Wiltshire, J. Briody et al., "Childhood chronic recurrent multifocal osteomyelitis: pamidronate therapy decreases pain and improves vertebral shape," Journal of Rheumatology, vol. 35, no. 4, pp. 707-712, 2008.
92. T. Hospach, M. Langendoerfer, T. von Kalle, J. Maier, and G. E. Dannecker, "Spinal involvement in chronic recurrentmultifocal osteomyelitis (CRMO) in childhood and effect of pamidronate," European Journal of Pediatrics, vol. 169, no. 9, pp. 1105-1111, 2010.
93. D. Eleftheriou, T. Gerschman, N. Sebire, P. Woo, C. A. Pilkington, and P. A. Brogan, "Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood," Rheumatology, vol. 49, no. 8, Article ID keq122, pp. 1505-1512, 2010.
94. H. Morbach, C. M. Hedrich, M. Beer, and H. J. Girschick, "Autoinflammatory bone disorders," Clinical Immunology, vol. 147, no. 3, pp. 185-196, 2013.
95. M. Sharma and P. J. Ferguson, "Autoinflammatory bone disorders: update on immunologic abnormalities and clues about possible triggers," Current Opinion in Rheumatology, vol. 25, no. 5, pp. 658-664, 2013.
96. C. L. Benhamou, A. M. Chamot, and M. F. Kahn, "Synovitisacne-pustulosis hyperostosis osteomyelitis syndrome (SAPHO): a new syndrome among the spondyloarthropathies?" Clinical and Experimental Rheumatology, vol. 6, no. 2, pp. 109-112, 1988.
97. B. C. Beretta-Piccoli, M. J. Sauvain, I. Gal et al., "Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome in childhood: a report of ten cases and review of the literature," European Journal of Pediatrics, vol. 159, no. 8, pp. 594-601, 2000.
98. K. B. Abdelghani, D. G. Dran, J.-E. Gottenberg, J. Morel, J. Sibilia, and B. Combe, "Tumor necrosis factor-α blockers in SAPHO syndrome," The Journal of Rheumatology, vol. 37, no. 8, pp. 1699-1704, 2010.
99. H. A. Majeed, M. Al-Tarawna, H. El-Shanti, B. Kamel, and F. Al-Khalaileh, "The syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia. Report of a new family and a review," European Journal of Pediatrics, vol. 160, no. 12, pp. 705-710, 2001.
100. P. J. Ferguson and M. Sandu, "Current understanding of the pathogenesis and management of chronic recurrent multifocal osteomyelitis," Current Rheumatology Reports, vol. 14, no. 2, pp. 130-141, 2012.
101. T. Herlin, B. Fiirgaard, M. Bjerre et al., "Efficacy of anti-IL- 1 treatment in Majeed syndrome," Annals of the Rheumatic Diseases, vol. 72, no. 3, pp. 410-413, 2013.
102. S. Reddy, S. Jia, R. Geoffrey et al., "An autoinflammatory disease due to homozygous deletion of the IL1RN locus," The New England Journal of Medicine, vol. 360, no. 23, pp. 2438-2444, 2009.
103. N. T. Haar, H. Lachmann, S. Özen et al., "Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review," Annals of the Rheumatic Diseases, vol. 72, no. 5, pp. 678-685, 2013.
104. I. Aksentijevich, S. L. Masters, P. J. Ferguson et al., "An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist," The New England Journal of Medicine, vol. 360, no. 23, pp. 2426-2437, 2009.
105. C. Schnellbacher, G. Ciocca, R. Menendez et al., "Deficiency of interleukin-1 receptor antagonist responsive to anakinra," Pediatric Dermatology, vol. 30, no. 6, pp. 758-760, 2013.
106. M. Stenerson, K. Dufendach, I. Aksentijevich, J. Brady, J. Austin, and A.M. Reed, "Thefirst reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist," Arthritis & Rheumatism, vol. 63, no. 12, pp. 4018-4022, 2011.
107. Y. Ueki, V. Tiziani, C. Santanna et al., "Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism," Nature Genetics, vol. 28, no. 2, pp. 125-126, 2001.
108. E. J. Reichenberger, M. A. Levine, B. R. Olsen, M. E. Papadaki, and S. A. Lietman, "The role of SH3BP2 in the pathophysiology of cherubism," Orphanet Journal of Rare Diseases, vol. 7, supplement 1, article S5, 2012.
109. M. Hero, A. Suomalainen, J. Hagström et al., "Anti-tumor necrosis factor treatment in cherubism-clinical, radiological and histological findings in two children," Bone, vol. 52, no. 1, pp. 347-353, 2013.
110. I. Pagnini, G. Simonini, M. Mortilla, T. Giani, L. Pascoli, and R. Cimaz, "Ineffectiveness of tumor necrosis factor-alpha inhibition in association with bisphosphonates for the treatment of cherubism," Clinical and Experimental Rheumatology, vol. 29, no. 1, p. 147, 2011.
111. S. C. Hill, M. Namde, A. Dwyer, A. Poznanski, S. Canna, and R. Goldbach-Mansky, "Arthropathy of neonatal onsetmultisystem inflammatory disease (NOMID/CINCA)," Pediatric Radiology, vol. 37, no. 2, pp. 145-152, 2007.
112. C. H. Sibley, N. Plass, J. Snow et al., "Sustained response and prevention of damage progression in patients with neonatalonset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes," Arthritis & Rheumatism, vol. 64, no. 7, pp. 2375-2386, 2012.